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I
t was 2000 when the scientific community first became widely aware
that perfluorooctanyl sulfonate (PFOS), then the key ingredient in
3M Company’s popular Scotchgard stain repellent, was being found
at extremely low levels throughout the environment and the human popu-
lation. Since that time, environmental scientists and toxicologists have
begun paying much more attention to PFOS, its sister compound perflu-
orooctanoic acid (PFOA; known for its use in DuPont’s Teflon products),
and other members of the family of perfluoroalkyl acids (PFAAs). As more
tests have been conducted, the research has revealed that laboratory ani-
mals respond in vastly different ways to PFAAs and related compounds,
which can make it difficult to pinpoint the mechanisms underlying the
responses. However, toxicologists are making headway in their under-
standing of these compounds, an important fact in light of new
research suggesting that the levels being found in both people and
animals may have an impact on their health.  
The tremendous variation in the speed with which humans and
laboratory animals can eliminate PFOA is one example of why
understanding how the compounds are processed in the body poses
such a formidable challenge. “You go from hours for the female rat,
to days for the male rat, to months for the monkey, to almost four
years in humans,” explains Jennifer Seed, a branch chief with the
EPA Office of Pollution Prevention and Toxics. 
“We truly don’t understand what are the biological events
that drive this difference,” says Christopher Lau, a lead research
biologist with the EPA National Health and Environmental
Effects Research Laboratory (NHEERL). “Are there binding
protein differences? Do humans have a different set of trans-
porters that is not the same as in animals?” Lau terms these gaps
in understanding “a black hole.”
These gaps render the toxicologist’s goal of extrapolating from
one species to another “a very complex state of affairs,” as Seed puts
it. For this reason, deciphering the human risk posed by exposure to
PFAAs is a major challenge, Lau says. “We need to go to the next level
to identify the underlying events that drive the adverse effects,” he says.T
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Anatomy of a PFAA
The compounds used in commercial
perfluorinated formulations are
sometimes identified by the number
of carbon atoms they contain. In
general, the longer the carbon chain
length, the more the PFAA persists in
the body, according to Naomi Kudo,
an associate professor of toxicology
and applied pharmacology at Josai
University in Japan. For example,
perfluorobutane sulfonate (PFBS),
which has 4 carbons, is eliminated in
a little over 1 month in humans, on
average, while PFOA and PFOS (so-
called C8 compounds with 8 carbons
each) are eliminated in 3.8 and 5.4
years, respectively. Perfluorohexane
sulfonate (PFHxS), with 6 carbons, is
an exception to the rule; it is elimi-
nated in 8.5 years. 
3M no longer manufactures PFOS,
and the compound is now used only
in relatively small quantities for
applications for which there is no
acceptable substitute, such as in
semiconductor manufacturing. All
eight of the companies currently
using PFOA—Arkema, Asahi, Ciba,
Clariant, Daikin, DuPont, 3M/Dyneon,
and Solvay Solexis—have agreed to
reduce PFOA releases and levels in
products by 95% by 2010 and to
eliminate their use by 2015. 
The new compounds being intro-
duced to replace PFOA and PFOS fall
into three general groups: the per-
fluoroalkyl sulfonates (a group that
includes PFOS), the perfluoroalkyl
carboxylates (including PFOA), and
the fluorotelomer alcohols, which are
used to produce perfluorinated surfac-
tants and polymers for products
including hair care products, paper products
used in direct contact with food, rug clean-
ers, and lubricants for bicycles, garden tools,
and zippers, according to the nonprofit
Environmental Working Group. 3M is
building its new PFAA products around
compounds containing fewer carbons,
including PFBS, because of their shorter
half-lives in humans, says John Butenhoff, a
corporate scientist in toxicology for 3M’s
Medical Department. 
But some of the new replacement com-
pounds may pose problems of their own.
More than 20 different such compounds
were discussed at a 14–16 February 2007
meeting of the Society of Toxicology (SOT)
on the toxicokinetics and mode of action of
PFAAs and related chemistries. For example,
fluorotelomer alcohols are emerging as the
main remaining source of PFOA in the
environment. These and other “residual”
compounds can be transformed into PFOA
or PFOS as the result of metabolism or envi-
ronmental biodegradation. In a presentation
at the SOT conference, Butenhoff noted that
1% of the total dose of 8-2 fluorotelomer
alcohol given to laboratory rats is metabo-
lized to PFOA. Similarly, other researchers
have observed that N-ethyl-N-(2-hydroxy-
ethyl)perfluorooctoanesulfonamide, a
constituent of coatings used on paper and
cardboard, can be transformed into PFOS
in the environment. It also may produce
PFOA in the atmosphere. 
Other PFAAs being detected in the
environment are also receiving more atten-
tion. The CDC detected not just PFOS and
PFOA but also PFHxS, perfluorononanoic
acid, and perfluorooctane sulfonamide in
every U.S. human blood sample from the
1999–2000 National Health and Nutrition
Examination Survey (NHANES) that was
analyzed for PFAAs, according to
Antonia Calafat, a lead research
chemist at the CDC’s National Center
for Environmental Health. In a paper
in the 1 April 2007 issue of Envi-
ronmental Science & Technology, CDC
researchers also reported finding two
compounds used in surfactants and
coatings on fabric, paper, and uphol-
stery—2-(N-ethyl-perfluorooctane
sulfonamido) acetic acid and 2-(N-
methyl-perfluorooctane sulfonamido)
acetic acid—in more than 90% of
the samples, she says. Similarly, per-
fluorobutyrate (a 4-carbon com-
pound) has been detected in surface
water and public and private wells.
Lau adds that PFOS and PFOA have
been found at locales near PFAA pro-
duction plants and waste disposal
facilities.
Polar Bears, Pandas, and People
Although a growing body of research
is focused on other PFAAs, PFOA and
PFOS have been the subject of the
lion’s share of study to date. Both com-
pounds are found throughout the
environment—from polar bears living
in Greenland, to giant pandas in
China, to albatrosses on the Midway
Atoll in the middle of the Pacific
Ocean. The compounds are also wide-
ly dispersed in surface waters, accord-
ing to 3M. 
At the SOT meeting in February,
researchers from the New Jersey
Department of Environmental Pro-
tection (NJDEP) reported detecting
PFOA in drinking water samples
from 78% of 23 treatment plants
sampled and PFOS in samples from
57% of the plants. The finding
prompted the NJDEP to recommend in
February 2007 that the state move toward
regulating PFOA in water. Currently New
Jersey recommends that the concentration
of PFOA in drinking water be less than
0.04 ppb. 
This value is significantly lower than the
Site-Specific Action Level of 0.5 ppb devel-
oped by the U.S. EPA as part of a consent
order in 2006 with DuPont for drinking
water in Ohio and West Virginia impacted
by DuPont’s Washington Works facility in
West Virginia. (This action level applies only
to the DuPont–West Virginia settlement;
there is no federal standard for PFOA in
drinking water.) The highly publicized C8
Study conducted by Edward Emmett and
colleagues the University of Pennsylvania has
examined drinking water exposures to PFOA
among Ohio and West Virginia residents liv-
ing near the Washington Works plant. At the
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Human exposure to PFAAs comes through myriad sources
including contaminated drinking water and household
products treated with stain or water repellants.Environmental Health Perspectives • VOLUME 115 | NUMBER 5 | May 2007 A 253
start of the study, the PFOA concentrations
in the blood serum of residents in Little
Hocking, Ohio, were  up to 89 times higher
than the U.S. average, according to a report
by Emmett in the August 2006 Journal of
Occupational and Environmental Medicine.
At press time, investigators on the study
expected any day to release results of whether
use of bottled drinking water had reduced
these concentrations. 
The NJDEP findings “suggest that
PFOA is commonly present in public water
systems not known to be specifically con-
taminated by a point source,” says Gloria
Post, a toxicologist with the department.
Additionally, Emmett’s Journal of Occupa-
tional and Environmental Medicine paper
indicates that even low concentrations of
PFOA in drinking water may significantly
contribute to levels found in the general
population.
People can also be exposed to PFOA and
PFOS due to poor disposal practices. In
Germany, industrial waste contaminated
with high concentrations of PFAAs was
mixed with soil by a recycling company.
Although the amended soil was later
declared illegal as a “soil improver,” it was
nonetheless used by farmers in the Arnsberg
agricultural area in the country’s North
Rhine–Westfalia state, according to Martin
Kraft of the state’s Ministry of the Environ-
ment and Conservation, Agriculture, and
Consumer Protection. When Kraft and his
colleagues analyzed how PFOA and PFOS
had spread through the environment, they
found concentrations of the two compounds
together reached 148 ppb in surface waters
and 0.6 ppb in drinking water, according to
a poster he presented at the SOT meeting.
The concentrations in edible fish including
trout, chub, and eel reached as high as
1.2  ppm, with a median of 133 ppb. In
comparison, similar fish from unpolluted
waters contained an average of 4 ppb.
PFOA was the predominant compound
detected in serum from the area’s people,
whose average serum levels of the compound
were 6 to 8 times higher than an unexposed
region of the country, Kraft says. In a
German-language government document
published 15 March 2007, Kraft and his col-
leagues reported that the average serum
PFOA concentration in Arnsberg children
was 22.1 ppb, in women it was 24.9 ppb,
and in men it was 27.4 ppb. 
For the U.S. population, CDC re-
searchers analyzed NHANES samples
collected in 1999–2000 to produce the first
nationally representative survey of PFAAs,
and these data are meant to serve as a base-
line, Calafat says. The average concentration
of PFOS in the 1,562 serum samples col-
lected from people aged 12 years and older
was 30.4 ppb, whereas the average concen-
tration of PFOA was 5.2 ppb. The levels in
men were slightly higher, on average, than
those in women, and the people with the
highest levels of the compounds also were
the most educated. 
PFOA and PFOS have also been detect-
ed in human breast milk and babies’ blood.
A Swedish study in the February 2007 issue
of EHP calculated that the total amount of
PFAAs transferred to breastfeeding infants
was approximately 200 ng/day. 
3M researchers have collected some evi-
dence that the company’s decision to phase
out production of materials including
PFOS and greatly reduce its use of PFOA
by the end of 2002 was already beginning
to affect levels of the compounds three
years later. In a pilot study published in
the May 2007 issue of Chemosphere, 3M
researchers compared concentrations of
PFOA and PFOS in plasma samples taken
from 40 American Red Cross donors in the
Minneapolis–St. Paul area in 2005 with
100 samples taken five years earlier from
the same general population. They found
that the average concentrations of both
PFOA and PFOS in the donor samples
dropped by more than 50% over that five-
year period, says Geary Olsen, a staff scien-
tist with 3M’s Corporate Occupational
Medicine Department.
The information gleaned from 3M’s
pilot study is not directly comparable to the
PFAA data from the 1999–2000 NHANES
because it is a random sample and not sta-
tistically representative of the U.S. popula-
tion, Olsen acknowledges. However, he
points out that a study of concentrations of
PFOA and PFOS in American Red Cross
donations in six cities in 2000, which was
published in the December 2003 issue of
EHP, produced numbers that were nearly
identical to what the CDC has reported for
the same time frame. 3M has just complet-
ed analyzing the samples from a follow-up
study conducted in 2006 that involves sam-
ples from the same six cities and expects to
submit them for publication later this year.
The company hopes these new data will
validate the drops in PFAA concentrations
seen in the pilot study, Olsen adds. 
Health Effects in Animal Studies
In animal studies, toxicologists have seen that
high doses of both PFOS and PFOA cause
cancer, physical development delays, endo-
crine disruption, and neonatal mortality. This
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PFAAs are ubiquitous in the environment, found on every continent in the world, 
in numerous mammal, fish, and bird species. last effect is arguably the most dramatic result
of laboratory animal tests with PFOS and
PFOA. “Animals are born, they look quite
healthy and pink, and then they die quite
rapidly,” Seed says. Other studies show
that the compounds can impact growth
and development and disrupt the body’s
hormone and immune systems.  
In older animals, toxicological studies
have shown that the compounds cause liver
and pancreatic tumors. A number of stud-
ies have demonstrated the ability of both
PFOS and PFOA to bind to peroxisome
proliferator–activated receptors (PPARs), a
class of receptors associated with carcino-
genesis. In addition to being investigated as
a cause of the cancers seen in laboratory
animals, PPAR activation is believed to
affect fetal growth and immune function. 
Much of the research conducted to
date has focused on the ability of PFAAs
to act as PPAR agonists by triggering
a response to a key receptor isoform,
PPAR-α. New research is beginning to
show that the compounds affect other
aspects of the body’s biochemistry, Seed
says; in fact, both PFOA and PFOS may
have multiple mechanisms of action. 
By working with mice genetically engi-
neered not to contain PPAR-α, Barbara
Abbott, a research biologist at NHEERL,
implicated that isoform in the neonatal
mortality caused by PFOA exposure.
Because PFOA is a fairly potent PPAR-α
agonist (much more so than PFOS), the
work suggests that different mechanisms
are responsible for the PFOS-induced
neonatal mortality seen in animals. “Both
PFOS and PFOA cause neonatal mortality,
and it is tempting to suggest that they have
the same mode of action, but in reality, they
may not at all,” points out John Rogers,
chief of the Developmental Biology Branch
of the NHEERL Reproductive Toxicology
Division.
At the SOT meeting, Kudo presented
research showing that the way male rats
process low doses of PFOA differs from
how they process high doses. These stud-
ies show that the compound is preferen-
tially taken up by the liver and is more
likely to be excreted from the liver into
the bile only at higher doses. Kudo’s
research may help account for why 3M
plant workers exposed to low doses tend-
ed to retain the compound in their bodies
for such long periods, while
laboratory rats exposed to
high doses quickly removed
the compound from their
bodies, she says. The work
may also explain why female
rats can rid their bodies of
PFOA so much more quickly
than males can, according to
Butenhoff.
Scientists have also made
some progress in understand-
ing how PFOA and PFOS
cause neonatal mortality in
laboratory mice. Researchers
at the EPA have determined
that newborn mice treated
with these substances that
appeared to be unable to
breathe were biochemically
mature and genetically nor-
mal, Rogers said at the SOT
meeting. The latest hypothe-
sis is that PFOS may impede
the function of the endoge-
nous pulmonary surfactant
needed to inflate the lungs,
he says. 
The Human Health
Impact
What does all this mean for
human health? To provide a
more useful context for com-
paring human data with the
insights derived from animal
studies, researchers working with laborato-
ry animals should be determining the con-
centrations of PFAAs in the bodies of their
test subjects, rather than simply reporting
the administered dose, stresses Melvin
Andersen, director of the Computational
Biology Division of The Hamner Institutes
For Health Research. 
Although most of the studies showing
adverse effects in laboratory animals
involved much higher levels of PFOS and
PFOA than are actually being seen in
humans and other animals, as-yet unpub-
lished research conducted at environmen-
tally relevant concentrations  suggests that
exposure at such levels may have an effect
on humans.
Researchers at The Johns Hopkins
University found PFOA in 100% and
PFOS in 99% of 297 serum samples col-
lected in 2004 and 2005 from the umbili-
cal cords of children born in Baltimore,
according to Lynn Goldman, a pediatrician
and epidemiologist at the Bloomberg
School of Public Health. Overall, the levels
were lower than in adults, but the highest
concentration of PFOS detected was
34.8 ppb, says Goldman, who stresses that
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Laboratory mice exposed
prenatally to PFOS and
PFOA develop more slow-
ly and suffer a higher rate
of neonatal mortality than
nonexposed mice (left).
Once exposed mice reach
adulthood, however, they
are more likely to become
obese (above).Environmental Health Perspectives • VOLUME 115 | NUMBER 5 | May 2007 A 255
these unpublished results need to be con-
firmed. The source of the PFOA and PFOS
in the infants’ blood was unclear, though
research published online 12 January 2007
in the Archives of Occupational and Environ-
mental Health suggests that transplacental
transfer may account for it. 
In addition to revealing a statistically
significant correlation between infants born
with higher levels of PFOS and PFOA and
decreased birth weight and head circumfer-
ence, the Johns Hopkins study unearthed a
correlation between the compounds and
the scores the babies earned on the ponder-
al index, which measures fetal body mass
and can serve as a rough approximation of
nutritional status. “The lower the ponderal
index, the higher the [cord serum] PFOS
and PFOA [concentrations],” Goldman
says. Other studies have suggested that low
birth weight may be a risk factor for obesi-
ty, diabetes, and cardiovascular diseases
later on. 
The Johns Hopkins researchers also cor-
related the babies’ PFOA (but not PFOS)
concentrations with their total circulating
thyroxine levels, Goldman says. Higher con-
centrations of PFOA and PFOS were linked
with longer gestational periods, as well. This
raises the question of whether these com-
pounds are transported more readily later in
pregnancy, or accumulate with the fetus
during pregnancy, says Goldman.
Unlike the CDC study, the Johns
Hopkins research did not find any correla-
tion between the socioeconomic status of
the parents and the children’s blood PFOA
and PFOS concentrations, which Gold-
man says is “quite remarkable.” Because
the babies were born into families from a
wide socioeconomic range, and because
other research points to consumer prod-
ucts as the source of the compounds,
Goldman says the new study suggests that
if consumer products are the source, “they
are the ones everyone in our [study] group
is using.”
Given the association in Goldman’s
research of higher levels of PFOS and
PFOA with lower ponderal index scores,
some researchers wonder if this finding
could tie in with new evidence connecting
high levels of PFOA in rodent pups to obe-
sity later in life. The research to date shows
that the offspring of exposed pregnant
mice have a dose-related increase in obesi-
ty, Rogers explains. “By the time they’re
obese,” he says, “they have very little
remaining PFOA and their liver is back to
normal size.” 
One hypothesis for why this is happen-
ing is that PFOA could be acting as a
hypolipidemic agent in increasing fatty
acid metabolism, according to Rogers. In
other words, the PFOA treatment is “essen-
tially asserting an [undernourished] envi-
ronment in utero.” 
“We know that these compounds affect
fatty acid metabolism,” Seed says. “Maybe
something is happening in the developing
organism that is interfering with the pro-
gram of energy metabolism.” 
Rogers says this fits with what is
known as fetal programming syndrome in
human infants, in which children who
experience a prenatal environment chroni-
cally short of nutrients and are then reared
with an abundance of food are more likely
to become overweight. “Whatever is hap-
pening that mediates its effects on lipid
metabolism, whether through PPAR-α or
otherwise, could be very important,” he
says. “We know very little about what’s
going with the fetus in terms of metabolic
programming. The environment, in a very
critical period of development, might
affect metabolism or shift metabolism for a
lifetime.” 
However, Lau points out that PFOA is
but one of a number of environmental con-
taminants that are being linked to adult
obesity. Follow-up research is in order to
more carefully pinpoint the events that lead
to obesity, perhaps by looking at gene
expression or protein markers for adipogen-
esis earlier in test animals’ lifetimes. 
More research is needed, agrees
Suzanne Fenton, the EPA research biolo-
gist who conducted most of the research
linking prenatal PFOA exposure in mice
with adult obesity. She says the latest data
suggest this effect is being seen at dosages
below 1 mg of PFOA per kg of body
weight (the actual amount of PFOA in the
animals’ blood was not determined). Her
studies also revealed PFAA-induced abnor-
malities in other mouse tissues, including
the ovaries, mammary glands, and spleen.
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Prenatal exposure to PFOS and PFOA can affect body weight and head circumference in
human infants. Postnatal exposures, as through breastfeeding, have unknown effects. Immunotoxicity: The Case of
Atlantic Dolphins
In light of research suggesting that PFOA
and PFOS both cause potent suppression of
the adaptive immune system, in 2006 the
EPA Science Advisory Board called for
immunotoxicity to be the subject of more
study. The EPA is currently conducting
such studies and has replicated findings
showing that PFOA suppresses the primary
immune response, says Robert Luebke, a
research biologist with the NHEERL
Immunotoxicology Branch. The researchers
are looking for PPAR-α activity, but there
are some indications that something else
may be going on, he says. He and his col-
leagues have noticed that the adrenal glands
of treated mice are somewhat enlarged,
which fits with reports that corticosteroid
levels rise in PFOA-treated animals. 
The first research to suggest that the
levels of PFAAs being detected in wild ani-
mals could be impacting their immune sys-
tems involved bottlenose dolphins believed
to have “the highest [PFOS levels] ever
reported in any wildlife species,” according
to Margie Peden-Adams, an assistant pro-
fessor at the Medical University of South
Carolina Department of Pediatrics and
Marine Biomedicine and Environmental
Science Center. At the SOT meeting, she
presented a poster discussing her work
with an international team that analyzed
blood samples collected from 89 dolphins
living near Charleston, South Carolina,
and Indian River Lagoon, Florida. The ani-
mals harbored concentrations of PFOA
that were approximately twice the levels
that the CDC found in U.S. citizens, but
their average levels of PFOS were 20 to 40
times higher, according to an analysis pub-
lished by a team of University of Guelph
researchers in the 1 October 2006 edition
of Environmental Science & Technology. 
In conjunction with collaborators at
Clemson University and the Mystic Aquar-
ium, Peden-Adams helped develop a suite
of assays to test immune function in the
bottlenose dolphin. “We did not find over-
whelming suppression [associated with
PFAAs],” she says. For example, the
researchers observed no alterations in T-cell
proliferation or NK-cell activity. However,
lysozyme activity was suppressed, B-cell
proliferation was stimulated, and numbers
of various lymphocytes increased. “The
immune system is very compensatory, and
often when one thing is suppressed, anoth-
er thing may be increased,” she says. 
“It is important to note that any devi-
ation on the continuum of possible
immune effects from normal homeostasis
is considered an alteration,” Peden-Adams
stresses. “Suppressed immune function
can lead to increased vulnerability to
pathogens, but enhanced immune func-
tion can be detrimental as well, leading to
hypersensitivity reactions, allergy, and
autoimmune reactions.” 
For comparison, Peden-Adams and her
colleagues dosed B6C3F1 mice with PFOS
at concentrations comparable to those
found in the dolphins. “The effects on
antibody production seen in the mice are
what would be expected based on studies
with PFOA and PFDA [perfluorodecanoic
acid] and . . . occurred at environmentally
relevant exposure levels as compared to
control animals,” she says. This new
research is noteworthy because no studies
to date have determined the immune
effects of PFOS, and “no other laboratories
we are aware of are assessing [these
effects],” Peden-Adams says.
Next Up for PFAA Research
The toxicological research conducted to
date wtih PFAAs shows “profound changes
in the biochemistry of [test] animals,”
Andersen says. “I believe that enough work
has been done to have a hypothesis that
most of the responses are coming from some
receptor-mediated processes.” Andersen
therefore proposes that it makes sense for
the research community to move forward
with low-dose studies that attempt to look
for genetic or genomic changes associated
with effects such as immunotoxicity and
reproductive toxicity. Rogers agrees,
although he points out that such low-dose
studies can be very difficult to conduct
because the effects are more subtle, and car-
rying them out can involve the use of hun-
dreds of test animals. 
“Doing more human population studies
is another approach,” says Goldman, who
adds that closer collaboration between toxi-
cologists and epidemiologists would aid
such an effort immensely. In animal studies,
toxicologists can “look directly at biomark-
ers and molecular changes in the brain, kid-
ney, and the liver—anywhere they wish—
whereas in human studies, we are limited by
what is available without creating an exces-
sive burden on research subjects,” she says. 
“If we’re going to bring the fields clos-
er together, we need to have human epi-
demiological research that is focusing more
on mechanisms,” Goldman adds. For
example, she says that environmental
health research would be much more rele-
vant to epidemiologists if toxicologists
would work toward identifying biomarkers
in human serum that are indicative of risk.
“If we’re interested in what the effects are
in humans, then one of the things I think
we need to do better is to begin thinking
about modes of action in people as well as
toxicology,” she concludes. 
Kellyn S. Betts
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Studies of bottlenose dolphins with some of the highest levels of PFOS reported in wild
animals indicate that the chemical may affect immune function. 
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